-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Today, Gilead Sciences announced that the U.
In 2020, approximately 580,000 people worldwide will be diagnosed with bladder cancer.
Trop-2 is highly expressed in various human epithelial cancers, including breast cancer, lung cancer, gastric cancer, colorectal cancer, pancreatic cancer, prostate cancer, cervical cancer, head and neck cancer and ovarian cancer.
Trodelvy is an antibody-conjugated drug composed of an antibody targeting Trop-2 and the active metabolite SN-38 of the chemotherapeutic drug irinotecan.
This accelerated approval is based on the results of a single-arm phase 2 clinical trial.
Note: The original text has been deleted
Reference materials:
[1] US FDA Grants Accelerated Approval to Trodelvy® for the Treatment of Metastatic Urothelial Cancer.